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Accepted 7 August 2015; Published online 18 August 2015AbstractObjective: Mendelian randomization is a popular technique for assessing and estimating the causal effects of risk factors. If genetic
variants which are instrumental variables for a risk factor are shown to be additionally associated with a disease outcome, then the risk
factor is a cause of the disease. However, in many cases, the instrumental variable assumptions are not plausible, or are in doubt. In this
paper, we provide a theoretical classification of scenarios in which a causal conclusion is justified or not justified, and discuss the inter-
pretation of causal effect estimates.
Results: A list of guidelines based on the ‘Bradford Hill criteria’ for judging the plausibility of a causal finding from an applied Men-
delian randomization study is provided. We also give a framework for performing and interpreting investigations performed in the style of
Mendelian randomization, but where the choice of genetic variants is statistically, rather than biologically motivated. Such analyses should
not be assigned the same evidential weight as a Mendelian randomization investigation.
Conclusion: We discuss the role of such investigations (in the style of Mendelian randomization), and what they add to our understand-
ing of potential causal mechanisms. If the genetic variants are selected solely according to statistical criteria, and the biological roles of
genetic variants are not investigated, this may be little more than what can be learned from a well-designed classical observational
study.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Genome-wide association studies have revealed genetic
predictors of many clinically relevant traits, including modi-
fiable risk factors and disease outcomes. Many investigators
have taken two such traits and considered the statistical
question of whether genetic variants that are associated with
trait A (often taken to be a risk factor and viewed as a pu-
tative cause) also show an association with trait B (often
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4.0/).heading of Mendelian randomization [1,2]. However, con-
clusions from such analyses have been diverse, ranging
from a direct causal interpretation (trait A causes trait B)
to one of shared etiology (trait A and trait B have common
predictors). In this article, we consider conditions under
which a causal interpretation is justified and discuss situa-
tions in which weaker conclusions are more appropriate.
2. Classification of scenarios
We consider the following classification of possible sce-
narios for the relationship between two variables A and B
such that genetic variant(s) associated with A are also asso-
ciated with B. An interventional definition of causality is
presumed; A is a cause of B means that intervention on
the distribution of A results in changes to the distribution
of B [3]. We assume that either logic or biological knowl-
edge is able to provide an ordering between A and B by
which A is the putative cause and B is the putative effect.
The three scenarios we consider are as follows:s article under the CC BY license (http://creativecommons.org/licenses/by/
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Fig. 2. Diagram illustrating causal relationships between genetic var-
iant(s) G, putative causal trait (risk factor) A, putative effect trait
(outcome) B, and confounders U necessary for instrumental variable
assumptions to be satisfied.
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 The popularity of Mendelian randomization as a
tool for investigating causal relationships in obser-
vational data is currently increasing.
 There is a distinction between Mendelian random-
ization as it was initially conceived and performed
(mainly for circulating biomarkers using few ge-
netic variants in relevant gene regions) and how
it is often used today (often opportunistically using
large numbers of genetic variants whose functional
relevance is unknown).
 Biological guidelines based on the Bradford Hill
criteria, and statistical criteria based on associa-
tions with measured covariates and homogeneity
of evidence across genetic variants are given to
help judge the plausibility of a causal conclusion.
 Causal claims should be reserved to cases where
the evidence for the instrumental variable assump-
tions is strong; otherwise the language of common
genetic predictors should be used.
1. A is a cause of B, and all causal pathways from the
genetic variant(s) to B pass through A;
2. A is a cause of B, but there are alternative causal
pathways leading from the genetic variant(s) to B
which do not pass through A;
3. A is not a cause of Bdthe genetic variant(s) are inde-
pendently associated with A and B.
Diagrams representing the relationships between the vari-
ables in each case are given in Fig. 1. We continue to
explore each of the scenarios mentioned previously in turn.
2.1. All causal pathways through risk factor
To infer a causal effect of A on B, it is necessary that
genetic variants used in the analysis satisfy the assumptions
of an instrumental variable [4,5]:
1. The set of genetic variants is associated with the risk
factor A;
2. Each genetic variant is independent of confounders of
the association between A and B;
3. If the risk factors were kept constant, intervention on
the genetic variant(s) would not have an effect on the
outcome.G
A
B
1.
G
A
B
2.
G
A
B
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Fig. 1. Diagrams illustrating scenarios of causal relationships between
selected genetic variant(s) G, putative causal trait A, and putative ef-
fect trait B, compatible with genetic variant(s) being associated with
both traits.A diagram corresponding to these assumptions is given
in Fig. 2.
These assumptions imply that all causal pathways from
the genetic variant(s) to the outcome pass through the puta-
tive causal risk factor, and there are no alternative pathways
not via the risk factor [6]. Formal considerations about how
causal pathways are defined are given in the Appendix at
www.jclinepi.com. The assumptions require that genetic
variants used for the assessment of the causal nature of a
risk factor must be specific in their associations with the
risk factor, although they may also show associations with
other variables via downstream effects of the risk factor.
For example, genetic variants that are candidate instru-
mental variables for body mass index (BMI) may show as-
sociations with C-reactive protein (CRP), because of a
causal effect of BMI on CRP [7]. This means that the ge-
netic variants can have associations with other variables
via mediation (ie, the genetic association with the other var-
iable is mediated via the risk factor of interest), but not via
pleiotropy (ie, the genetic association with the other vari-
able is via a different causal pathway and not via the risk
factor of interest; Fig. 3).
If we seek to assess whether there is a causal effect of A
on B, but not to provide an estimate of a causal effect
parameter, then only the three instrumental variable as-
sumptions listed previously are required. Under these as-
sumptions, an association between the outcome B and
genetic variants which are instrumental variables for A im-
plies a causal effect of A on B [8]. To estimate a causal ef-
fect parameter, further assumptions are required [9],
including linearity of the risk factoreoutcome association,
and the stable unit treatment value assumption (the value of
the outcome for each individual depends on the value of theG AM
Pleiotropy:
G A M
Mediation:
Fig. 3. Diagrams illustrating the difference between pleiotropy (left),
where genetic variant G is independently associated with traits A
and M, and mediation (right), where G is associated with trait M only
via the effect of A.
G C
A
B
Fig. 4. Diagram illustrating additional scenario of causal relationships
between selected genetic variant(s) G, underlying putative causal trait
C, measured proxy variable A, and putative effect trait B, compatible
with genetic variant(s) being associated with both traits A and B (con-
founding variables are omitted from the diagram).
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tor was intervened on) [10].
Mendelian randomization can be understood as being
similar to a randomized controlled trial, in which genetic
variants play the role of random assignment to a treatment
group [11]. However, in a randomized trial, the goal is to
assess the effect of different treatment strategies between
randomized subgroups with the purpose of implementing
one of the strategies, whereas in Mendelian randomization,
the goal is to assess the effect of a difference in the distri-
butions of a risk factor between genetically determined sub-
groups, with the purpose of implementing a nongenetic
intervention on the risk factor. The genetically determined
differences in the risk factor are likely to differ from any
proposed intervention on the risk factor in a number of
qualitative and quantitative ways: in particular because of
the duration of the intervention (life long or short term),
the magnitude of the intervention (genetic effects are usu-
ally small, clinical interventions are typically larger), and
the mechanism of the intervention (genetic effects and clin-
ical interventions may operate via different pathways) [12].
As different ways (including timing, duration, mechanism,
and magnitude) of intervening on the risk factor will typi-
cally lead to different magnitudes of effect on the outcome,
it is likely that the causal effect estimate from a Mendelian
randomization study differs quantitatively from the effect
of a proposed intervention in the risk factor. Hence, even
in a scenario in which the genetic variant(s) are valid instru-
mental variables and the risk factor-outcome relationship is
linear, a causal effect estimate from a Mendelian randomi-
zation study should not be interpreted literally as the ex-
pected outcome of an intervention on the risk factor of
interest.
For this reason, some authors have questioned whether
causal effect estimates should ever be presented as part of
a Mendelian randomization analysis [13]. Although a
causal estimate in a Mendelian randomization study will
typically differ from the expected result of a clinical inter-
vention on a risk factor, there are practical reasons why it
may be beneficial to provide a causal estimate in a Mende-
lian randomization study, provided the magnitude of this
estimate is not overinterpreted.
 Generally in epidemiology, estimates with confidence
intervals are preferred to hypothesis tests with P-
values, as they are more informative [14]. If a P-value
does not achieve conventional levels of statistical sig-
nificance, a point estimate with a confidence interval
allows the reader to judge in a quantitative way
whether the null result reflects a lack of evidence or
a genuine negative finding in comparison with either
the observational association, or with a minimal clini-
cally relevant effect. If the confidence intervals for the
causal effect exclude the minimal clinically relevant
effect, then the causal effect for all practical purposes
is null, particularly as Mendelian randomizationestimates often overestimate the effects of intervening
on risk factors in practice (as they represent life-long
effects) [12]. Additionally, a magnitude of causal ef-
fect must be proposed to perform a formal power
calculation [15]. This is particularly important in Men-
delian randomization analyses, which often suffer
from limited power to detect a causal effect of poten-
tial clinical interest [16].
 If several genetic variants are valid instrumental vari-
ables for the same risk factor, greater power to detect
a clinically relevant causal effect can be obtained us-
ing information on all the variants simultaneously
rather than that using the variants individually [17].
It may be that no variant individually provides strong
evidence for a causal effect of the risk factor based
solely on its association with the outcome, but the
combination of evidence from all of the variants does.
Causal estimates from multiple variants also enable
the quantitative comparison of the consistency of ge-
netic associations, using a heterogeneity or overiden-
tification test as a statistical assessment of pleiotropy
[18].
 Although a causal estimate from a Mendelian
randomization investigation will not correspond pre-
cisely to the expected effect of a intervention in the
risk factor (which will in any case differ between in-
terventions), it does represent the outcome of a well-
defined intervention, namely in the genetic code at
conception. As such, it will be a more relevant indica-
tor of the predicted effect of a clinical intervention in
the risk factor if the intervention acts in a similar way
to the genetic variant; for example, if the genetic
variant and the intervention affect the same biological
pathway, if the magnitudes of change in the risk fac-
tor are similar, and if long-term changes in the risk
factor are considered.
In summary, if the only causal pathways from the ge-
netic variant(s) to the outcomes are via the risk factor of in-
terest, then the causal hypothesis of the risk factor on the
outcome can be reliably assessed, although a numerical
causal estimate will be at best an approximation to the ef-
fect of intervening on the risk factor in practice.
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Often, the associations of a genetic variant are not
restricted to the risk factor of interest. ‘‘Off-target’’ genetic
associations, including pleiotropic effects and associations
arising from linkage disequilibrium, may lead to violation
of the instrumental variable assumptions by providing an
alternative pathway from the genetic variant(s) to the
outcome not via the risk factor [6]. If a genetic variant vi-
olates the instrumental variable assumptions, then any
assessment of causality using that variant will be unreliable
[19,20].
We consider an alternative set of assumptions (scenario
2a, Fig. 4) under which there may be an alternative causal
pathway from the genetic variant(s) to the outcome not via
the risk factor, but testing the genetic associations with the
outcome still provides a valid test of the null hypothesis of
no causal relationship. In this case, we assume that the ef-
fect of the genetic variant(s) is via an underlying causal var-
iable C, and the measured risk factor is a surrogate (or
proxy) measure of the underlying causal variable(s). For
example, BMI can be used as a surrogate measure of
obesity. Provided that all the genetic variants used in a
Mendelian randomization analysis are exclusively associ-
ated with some aspect of obesity that is captured by BMI,
associations of the genetic variants with the outcome are
indicative of a causal role of obesity in disease risk. How-
ever, unless a specific causal risk factor can be identified
such that all causal pathways from gene to disease run
via that risk factor, no more detailed causal claim can be
made [21]. In particular, any causal effect estimate will
be an even more distant approximation of the potential
result of intervening on the risk factor in practice.
Another example of scenario 2a, where the instrumental
variable assumptions are not formally satisfied, but a Men-
delian randomization analysis may be informative, involves
genetic variants associated with smoking. The associations
with lung cancer of certain genetic variants related to smok-
ing did not appear to be mediated by a measure of smoking
intensity, the number of cigarettes smoked per day [22]. A
Mendelian randomization estimate expressed as the causal
effect of number of cigarettes per day on lung cancer risk
using one variant gave an odds ratio estimate of 2180, an
implausibly large effect [13]. This could be interpreted as
meaning that the instrumental variable assumptions are
not satisfied, as there appears to be an alternative causal
pathway from the genetic variants to the outcome not via
smoking intensity. However, an alternative interpretation
would be that smoking intensity is a proxy measure of
the true underlying causal risk factor, but an imprecisely
measured proxy, so that the estimate provides a valid test
of the causal null hypothesis, but the causal effect is over-
estimated. The general conclusion that smoking-related be-
haviors are causally related to lung cancer risk, rather than
a specific conclusion about the causal effect of smoking in-
tensity, is more appropriate according to the geneticevidence. A proposal as to the underlying causal risk factor
in this case is the amount of nicotine extracted from each
cigarette [23]. This scenario is likely to occur for complex
exposures that have multiple potential causal pathways.
2.3. No causal effect of risk factor
If the instrumental variable assumptions are not satisfied,
genetic variants may be associated with a risk factor and an
outcome without a causal effect of the risk factor on the
outcome. For instance, genetic variants may be associated
with a common cause of the risk factor and outcome. Var-
iants in the IL6R gene region have been shown to be asso-
ciated with CRP (an inflammation marker) and with
coronary heart disease risk [24,25]; however, it is thought
that interleukin-6 (an upstream marker of inflammation)
pathways are causal for coronary heart disease and not
CRP itself (as focused Mendelian randomization investiga-
tions using variants in the CRP gene region have suggested
a null causal effect of CRP on coronary heart disease risk
[26]). If variants in the IL6R gene region were assumed
to be instrumental variables for CRP, then the false conclu-
sion would be reached that CRP was causal for coronary
heart disease risk. Although in this case, the use of variants
in the IL6R gene region as instrumental variables for CRP
would be an elementary mistake, in cases where the causal
gene and the biological pathway it affects are not known,
misleading conclusions could be reached.
Even if the risk factor would seem logically to take the
role of the cause and the outcome of the effect, a reverse
causal explanation is possible. For example, although in-
flammatory biomarkers may be thought of as a potential
cause of coronary heart disease, it may also be that subclin-
ical disease leads to elevated levels of the biomarkers [27].
Genetic variants associated with coronary heart disease risk
via alternative causal pathways may show associations with
inflammatory markers because of a reverse causal effect.
It is also important to appreciate that the causal question
addressed by a Mendelian randomization is whether long-
term elevated (or reduced) levels of a risk factor will affect
the outcome. For example, the null causal effect of CRP on
coronary artery disease risk estimated using genetic vari-
ants having modest associations with CRP levels [26] sug-
gests that the development of pharmacological agents to
suppress usual CRP concentrations is not likely to be effec-
tive in reducing coronary heart disease incidence. The
causal question about long-term levels of the risk factor
is usually the relevant question for epidemiologic research.
Distinguishing scenarios 1 and 2, where the risk factor is
a cause of the outcome, from scenario 3, where the two have
common genetic predictors but are otherwise independent, is
not empirically possible and requires biological knowledge.
As such, if the instrumental variable assumptions in a
particular applied investigation are uncertain, a more
tentative conclusion is appropriate. In practice, the distinc-
tion between more plausible Mendelian randomization
Table 1. Bradford Hill criteria applied to Mendelian randomization for judging plausibility of instrumental variable assumptions
The Bradford Hill criteria [28] form a systematic summary of common-sense principles for judging causality that are as relevant in genetic
epidemiology as they are in classical epidemiology. We apply each of the relevant criteria to genetic variants for use in Mendelian randomization
investigations:
Strength: If a genetic association with the outcome is slight, then the power of a Mendelian randomization analysis may be low. Additionally, causal
estimates are more sensitive to small violations of the instrumental variable assumptions [29]. However, the magnitude of association of a
genetic variant with the outcome is not indicative of the importance of that biological pathway in disease risk; if the risk factor can be intervened
on by a greater extent than the genetic association (as is often the case with pharmacologic interventions), then a greater impact on the disease
outcome may be observed.
Temporality: As the DNA sequence of an individual is determined at conception, genetic associations are protected from bias due to reverse
causation. Genetic variants must always precede the associated variable in time. However, inferring a causal effect of the risk factor on the
outcome (rather than the other way round) requires an assumption that the proximal association of the genetic variant is with the risk factor, not
with the outcome (nor with an alternative cause of the outcome).
Consistency: A causal relationship is more plausible if multiple genetic variants associated with the same risk factor are all directionally concordant
in their associations with the outcome, especially if the variants are located in different gene regions and/or have different mechanisms of
association with the risk factor.
Biological gradient: Furthermore, a causal relationship is more plausible if the genetic associations with the outcome and with the risk factor for
each variant are proportional. For example, genetic associations with low-density lipoprotein cholesterol and with coronary artery disease risk
provide evidence of a dose-response relationship, with variants having a greater per allele association with low-density lipoprotein cholesterol also
having a greater per allele odds ratio of coronary artery disease [30].
Specificity: A causal relationship is more plausible, if the genetic variant(s) are associated with a specific risk factor and outcome and do not have
associations with a wide range of covariates and outcomes. A specific association is most likely if the genetic variant(s) are biologically proximal
to the risk factor, and not biologically distant. This is most likely for risk factors that are proteins or metabolites (such as C-reactive protein and
uric acid), rather than complex risk factors (such as body mass index and blood pressure).
Plausibility: A causal relationship is more plausible if the function of the genetic variant(s) is known and if the mechanism by which the variant acts
is credibly and specifically related to the risk factor.
Coherence: If an intervention on the risk factor has been performed (eg, if a drug has been developed that acts on the risk factor), associations with
intermediate outcomes (covariates) observed in the experimental context should also be present in the genetic context; directionally concordant
genetic associations should be observed with the same covariates. For example, associations of genetic variants in the IL1RN gene region with C-
reactive protein and interleukin-6 should be similar (at least directionally concordant) to those observed in randomized trials of anakinra, the
recombinant form of interleukin-1 receptor antagonist [31].
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assessment and will give a continuous scale of evidential
quality rather than a dichotomy of ‘‘good’’ and ‘‘bad’’
studies. In the next section, we consider some criteria to help
judge the plausibility or otherwise of a Mendelian randomi-
zation investigation.3. Assessing the assumptions necessary for causation
Justification of the instrumental variable assumptions can
be provided using biological knowledge and statistical
testing. In Table 1, we apply the Bradford Hill criteria for
causation toMendelian randomization as a checklist to judge
whether a causal conclusion based on the genetic variant(s) is
warranted. Of particular interest is the tension between using
large numbers of genetic variants, which allows increased
power for the assessment of the consistency of the causal ef-
fect and its biological gradient across different variants, and
specificity, which suggests that an analysis should be limited
to variants in those gene regions that most credibly satisfy the
instrumental variable assumptions.
The Bradford Hill criteria also suggest that variants from
candidate gene investigations, where the function of the ge-
netic variant(s) is well-understood, will have more credi-
bility for use in Mendelian randomization studies than
variants with unknown functional relevance, such as those
often discovered in genome-wide association studies.Additionally, the utility for translational research of such
an analysis will be increased, as a genetic variant with
well-understood biology associated with a causal risk factor
often indicates a potential pathway for intervention on the
risk factor [32]. For instance, genetic variants in the HMGCR
and PCSK9 gene regions associated with low-density lipo-
protein cholesterol and coronary heart disease risk suggest
that inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (HMGCR) and of proprotein convertase subtili-
sin/kexin type 9 (PCSK9) would reduce low-density lipopro-
tein cholesterol levels and therefore be protective of
coronary heart disease risk; the former mechanism is how
statin drugs act [33], and the drugs targeting the latter mech-
anism are already in late-stage development [34,35].
Although the instrumental variable assumptions cannot
be statistically proven, implications of the assumptions
can be tested [21]. The associations of genetic variants with
measured covariates can be tested. A valid instrumental var-
iable should be associated with the risk factor but not with
other covariates unless they are causally downstream of the
risk factor. Indeed, if there are variables that are known to
be causally related to the risk factor, the genetic associa-
tions with these variables can be tested as a ‘‘positive con-
trol.’’ The consistency of associations of different genetic
variants can be assessed visually, in a graph of the per allele
genetic associations with the outcome against the per allele
associations with the risk factor for each variant (which,
apart from random sampling variation, should be a straight
213S. Burgess et al. / Journal of Clinical Epidemiology 69 (2016) 208e216line through the origin), and formally by a heterogeneity
test [36] (also known as an overidentification test [37]). De-
parture from a linear relationship may be an indication of
pleiotropy. Any outliers on this graph should be examined
closely for pleiotropic associations that might explain the
genetic association with the outcome. This is particularly
important when an allele score (also known as a gene score
or genetic risk score) is used to obtain inferences [38]; the
overall association of an allele score with the outcome may
conceal inconsistencies in the analysis, such as genetic var-
iants having different directions of association with the
outcome. Additionally, a funnel plot can be plotted of the
instrumental variable estimate on the basis of each genetic
variant in turn against the association of the variant with the
risk factor. Asymmetry in the funnel plot would also be ev-
idence of differences between estimates from weaker and
stronger genetic variants, another possible indication of
pleiotropy [39].4. Joint association studies
Recently, several investigators have considered genetic
variants associated with a risk factor and their association
with an outcome variable in the absence of biological knowl-
edge about the genetic variants. For example, investigators
have taken all the genetic variants associated with height at
a genome-wide level of statistical significance and considered
whether these variants also predict colorectal cancer risk [40].
Although it is impossible to ever have complete biological
knowledge about genetic variants to justify the instrumental
variable assumptions in a Mendelian randomization investi-
gation, in these studies, the choice of genetic variants is pri-
marily motivated by statistical rather than biological
considerations. The instrumental variable assumptions are
investigated in a post-hoc way, if at all. We assert that these
investigations, although they may use the statistical method-
ology of Mendelian randomization, are not true Mendelian
randomization investigations.
To distinguish these analyses from well-justified Mende-
lian randomization analyses, we use the term ‘‘joint associa-
tion study’’ as the joint association of variants with a risk
factor and an outcome is assessed. A non-null finding from a
joint association study will still provide suggestive evidence
of a causal effect, or of shared causal mechanisms, through
the conclusion of common genetic predictors [41]. Although
a joint association study is not able to assess a causal relation-
ship in a reliable way, a relevant practical question is how to
perform and interpret such an analysis so as to provide the best
possible evidence for causal inference.5. Performing a joint association study
If there is insufficient biological knowledge to justify the
instrumental variable assumptions for a set of candidategenetic variants, several approaches for the selection of var-
iants can be taken as follows.
5.1. Conservative approach
If the instrumental variable assumptions can be justified
or are more plausible for a subset of variants, then the pri-
mary analysis should be based on these variants, and a more
speculative analysis using more variants (but potentially hav-
ing greater power) should be viewed as a secondary analysis.
5.2. Liberal approach
If the instrumental variable assumptions cannot be justi-
fied biologically, an analysis can be performed using those
variants which are associated with the risk factor of interest,
but not associated with measured covariates which are po-
tential confounders. Although this approach does not
address the difficulty of unknown and unmeasured con-
founders, sensitivity analyses can be performed to give a
sense as to how robust the finding is to violation of the
instrumental variable assumptions [42].
5.3. Data-driven (post hoc) approach
Alternatively, a data-driven approach has been proposed
on the basis of a heterogeneity test statistic for the causal
effect estimates from multiple genetic variants [36]. If the
statistic exceeds a critical value of the chi-squared distribu-
tion (say, the 95th percentile), then a stepwise selection pro-
cedure can be followed, omitting the variant whose
contribution to the heterogeneity statistic is the greatest, un-
til the statistic is below the critical value [43].
There are several potential pitfalls with such an
approach. First, it is necessary to assume that most genetic
variants do satisfy the instrumental variable assumptions, so
that the outlying variants removed in the stepwise selection
are the invalid variants. Second, even if all genetic variants
are valid instrumental variables, some heterogeneity in their
associations with the outcome would be expected, particu-
larly if the genetic variants influenced the same risk factor
via different causal pathways. Third, as with all post-hoc
analyses in which the analysis method is determined on
the basis of the observed data, there is likely to be bias in
the effect estimates. If associations of most genetic variants
lie on a straight line with a limited number of rogue vari-
ants, then a post-hoc analysis may be a reasonable sensi-
tivity analysis. If there is considerable heterogeneity
between variants with no discernible pattern of association,
then results from a data-driven analysis will not be reliable.
5.4. Whole-genome approach
Afinal alternative is awhole-genome approach, where ge-
netic variants from throughout the genome are included in an
analysis. It has also been suggested that investigations with
large numbers of genetic variants may be fruitful [44];
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An analysis using genome-wide genetic scores for various
risk factors gave false negative and false positive results; it
suggested that CRPwas a causal risk factor for coronary heart
disease risk (P 5 0.028), but BMI was not (P 5 0.37) and
suggested an inverse effect of low-density lipoprotein choles-
terol on hypertension (P5 0.011) and on type 1 diabetes risk
(P 5 0.018) [45]. A more recent analysis using publicly
available summarized data on genetic associations using a
novel methodologic approach gave more plausible results,
although again showed weak to null associations for the es-
tablished risk factors of obesity and low-density lipoprotein
cholesterol with coronary artery disease risk [46].6. Interpreting a joint association study
If genetic variants associated with two traits overlap,
this increases the likelihood that the traits have related bio-
logical mechanisms. For example, genetic approaches have
been used in the nosology of psychiatric disorders to
inform the degree to which separately classified diseases
may be related [47]. Here the aim was not to assess a
particular causal risk factor, but to increase or decrease
the general plausibility that similar causal mechanisms un-
derpin each of the disease traits. A genetic approach to as-
sessing the relatedness of two traits is likely to give
mechanistic insights beyond what can be obtained from
an observational study if common genetic pathways pre-
dicting the traits can be identified. Additionally, genetic
variants tend not to be associated with socioeconomic or
environmental factors, which are difficult to measure in
observational research [48]. They are also fixed at concep-
tion, so cannot be affected by changes in external variables
that may lead to reverse causation in observational studies.
Hence, even if the instrumental variable assumptions are
not satisfied, a joint association study offers some benefit
over an observational analysis in terms of reduced con-
founding and reverse causation. Finally, genes have func-
tional relevance in biological processes, so shared genetic
associations are more likely to represent shared biological
rather than nonbiological predictors.
However, the complete separation of biological from
nonbiological effects usingpopulationgenetics is not possible.
For example, a genetic variant associated with both alcohol
consumption and cannabis use has been interpreted as evi-
dence in the hypothesis that alcohol consumption causes
increased cannabis consumption [49]. However, the conse-
quences of having the alcohol-related genetic variant are not
limited to biological effects. The decreased propensity to drink
alcohol associated with the null form of the genetic variant
would also have effects not confined to the biological effect
of alcohol consumption. For example, those who do not drink
alcohol are also less likely to attend social events at which
alcohol is served. The causal effect assessed by a Mendelian
randomization experiment in this case is therefore not simplythe biological effect of alcohol consumption, but also the so-
cial effect of being an alcohol consumer.
Although a joint association analysis can increase or
decrease the plausibility of a causal relationship, there are
many limitations to such an analysis. This means that the
evidential weight of such an analysis in terms of proving or
disproving causation should not be as great as that of a Men-
delian randomization study inwhich the instrumental variable
assumptions are strongly supported by biological and statisti-
cal justification. An analysis where the choice of genetic var-
iants is made solely on the basis of observational data and the
biological pathways affected by the variants are not investi-
gated should not carry much more evidential weight for
demonstrating a causal relationship than awell-designed clas-
sical (nongenetic) observational study.7. Conclusion
Mendelian randomization has been defined as ‘‘using
genes as instrumental variables for making causal infer-
ences’’ [2]. As such, if the instrumental variable assumptions
are not satisfied, an analysis to demonstrate shared genetic
predictors of a risk factor and outcome is not Mendelian
randomization, even if the statisticalmethodology ofMende-
lian randomization (instrumental variable analysis) is used.
Mendelian randomization has been advocated as
providing strong evidence for causal relationships and has
been placed in a hierarchy of evidence only below well-
designed randomized controlled trials [50]. However, the
quality of evidence provided by a Mendelian randomization
study relies heavily on the instrumental variable assump-
tions. Although the finding of shared genetic predictors is
consistent with a causal relationship between the risk factor
and outcome and increases the plausibility of either the spe-
cific risk factor or a mechanism related to the risk factor
having a causal effect on the outcome, it is also consistent
with the risk factor and outcome simply sharing common
predictors. Although speculative ‘‘Mendelian randomiza-
tion’’ analyses, such as those based on variants of unknown
biological relevance discovered in a genome-wide associa-
tion study, have a role in the scientific literature (as do
observational studies and many other designs), results will
be far less reliable than those from analyses where the bio-
logical role of the genetic variants is well established.
Claims of the causal (or noncausal) role of a particular risk
factor should be reserved to those where there is strong ev-
idence (biological and statistical) supporting the instru-
mental variable assumptions, and the weaker claim of
common genetic predictors should be made in other cases.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.08.001.
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